A detailed history of Vanguard Group Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,871,375 shares of CGEM stock, worth $47.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,871,375
Previous 1,774,345 61.83%
Holding current value
$47.3 Million
Previous $30.2 Million 65.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$15.63 - $29.35 $17.1 Million - $32.2 Million
1,097,030 Added 61.83%
2,871,375 $50.1 Million
Q1 2024

May 10, 2024

BUY
$10.17 - $19.02 $29,513 - $55,196
2,902 Added 0.16%
1,774,345 $30.2 Million
Q4 2023

Feb 14, 2024

BUY
$7.89 - $10.23 $654,159 - $848,169
82,910 Added 4.91%
1,771,443 $18.1 Million
Q3 2023

Nov 14, 2023

SELL
$9.05 - $11.72 $3.07 Million - $3.97 Million
-338,873 Reduced 16.71%
1,688,533 $15.3 Million
Q2 2023

Aug 14, 2023

SELL
$8.8 - $13.4 $4.64 Million - $7.07 Million
-527,582 Reduced 20.65%
2,027,406 $21.8 Million
Q1 2023

May 15, 2023

SELL
$10.2 - $11.91 $2.63 Million - $3.07 Million
-257,977 Reduced 9.17%
2,554,988 $26.1 Million
Q4 2022

Feb 10, 2023

BUY
$9.72 - $13.62 $466,171 - $653,215
47,960 Added 1.73%
2,812,965 $29.7 Million
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $230,324 - $300,474
19,486 Added 0.71%
2,765,005 $35.4 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $13.55 $2.88 Million - $5.33 Million
393,394 Added 16.73%
2,745,519 $35.2 Million
Q1 2022

May 13, 2022

SELL
$10.47 - $16.75 $153,731 - $245,940
-14,683 Reduced 0.62%
2,352,125 $24.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.36 - $25.0 $1.31 Million - $2.13 Million
85,357 Added 3.74%
2,366,808 $36.5 Million
Q3 2021

Nov 12, 2021

BUY
$22.56 - $29.68 $25.4 Million - $33.4 Million
1,125,686 Added 97.4%
2,281,451 $51.5 Million
Q2 2021

Aug 13, 2021

BUY
$24.96 - $41.25 $28.8 Million - $47.7 Million
1,155,765 New
1,155,765 $29.8 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $752M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.